Sanofi Pasteur Selects Freeslate to Improve Formulation Development - - BioPharm International

ADVERTISEMENT

Sanofi Pasteur Selects Freeslate to Improve Formulation Development



Freeslate, a provider of high-throughput research solutions, reports that Sanofi Pasteur, the vaccines division of Sanofi, has purchased Freeslate’s Biologics Formulation System, which is usual in vaccine and protein formulation development. The system automates sample preparation, sample stressing, and formulation analysis, to allow for the development of stable, robust formulations more quickly with reduced API consumption.

Based on the Freeslate Core Module 3 automation platform, the Biologics Formulation System combines liquid dispense and controlled heating/cooling/mixing with new automated measurements of pH, viscosity, and particle counting. Integrated by Freeslate’s Lab Execution and Analysis software suite, the system allows for the control and data integration of a range of third-party analytics, including Dynamic Light Scatter, UV/VIS plate readers, and high pressure liquid chromatography.

Source: Freeslate

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines

Click here